Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Email

Lipid nanoparticles for overcoming biological barriers to mRNA delivery

Division of Cancer Treatment and Diagnosis Technology Development Seminar Series

December 1, 2026 | 11:00 AM – 12:00 PM

Virtual

Add to Outlook Calendar

National Cancer Institute Division of Cancer Treatment and Diagnosis Technology Development Seminar Series

The National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis invites you to join the Technology Development Seminar Series with Dr. Michael J. Mitchell on December 1, 2026, from 11:00 am-12:00 pm ET. 

Speaker selected by the Developmental Therapeutics Program. 

Advance registration is required. Register here.

Dr. Michael J. Mitchell

Michael J. Mitchell is the Hibbert Professor of Bioengineering at the University of Pennsylvania, and the Lipid Nanoparticle Delivery Systems Group Leader at the Penn Institute for RNA Innovation. He received a BE in Biomedical Engineering from Stevens Institute of Technology in 2009, a PhD in Biomedical Engineering with Prof. Michael King from Cornell University in 2014. He was a Postdoctoral Fellow in Chemical Engineering with Prof. Robert Langer at MIT from 2014-2017, prior to pursuing his independent career at University of Pennsylvania in 2018. Mitchell is an internationally recognized expert in lipid nanoparticle technologies for the delivery of mRNA and other genetic medicines. His interdisciplinary research bridges biomaterials science, drug delivery and molecular engineering, with applications ranging from cancer immunotherapy and vaccines, genome editing, aging, cardiovascular disease, and fetal and maternal therapeutics. 

Mitchell has authored over 200 peer-reviewed publications, including those in Nature, Nature Biotechnology, Nature Materials, Nature Chemistry, Nature Nanotechnology, Nature Cancer and Nature Biomedical Engineering. He is an inventor on over 80 pending or awarded patents, and is a co-founder and serves on the Scientific Advisory Board of numerous biotechnology companies focused on developing non-viral delivery technologies for genetic medicines. His work has earned numerous distinctions, including the National Science Foundation CAREER Award, the NIH Director’s New Innovator Award, Penn’s Emerging Inventor of the Year Award and Young Investigator Awards from the Society for Biomaterials and the Controlled Release Society. He has also been twice-designated a Clarivate World’s Top 0.1% Highly Cited Researcher, elected a Fellow of the Controlled Release Society, and received the Kabiller Rising Star Award.

Read about past presenters and view available recordings for select seminars here. 

Contact Jung S. Byun, PhD, MPH for more information.

Email